Cefepime is a fourth-generation cephalosporin antibiotic used to treat a wide range of serious bacterial infections. It was approved by the FDA in 1996 and is typically administered intravenously in hospital or clinical settings. Cefepime works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death, and is effective against both Gram-positive and Gram-negative organisms, including many resistant strains. It has good penetration into various body tissues and fluids, making it useful in treating conditions such as pneumonia, urinary tract infections, skin infections, and febrile neutropenia. Cefepime is generally considered safe and effective when used appropriately, although side effects such as gastrointestinal disturbances and, in rare cases, neurotoxicity may occur, especially in patients with impaired kidney function.
BRAND NAMES
Maxipime
Cepimax
Cefepime Injection (generic brands available worldwide)
MECHANISM OF ACTION
The mechanism of action of Cefepime is by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), preventing proper formation of the cell wall, which leads to weakening and rupture of the bacterial cell, ultimately causing cell death.
PHARMACOKINETICS
Absorption
The absorption of Cefepime is not applicable via the oral route, as it is poorly absorbed from the gastrointestinal tract. Therefore, it is administered parenterally, usually by intravenous or intramuscular injection, which ensures complete bioavailability.
Distribution
The distribution of Cefepime shows a volume of distribution of about 0.25 L/kg, with good penetration into body tissues and fluids such as the lungs, kidneys, and cerebrospinal fluid. It has low protein binding (around 15–20%), allowing effective delivery to infection sites.
Metabolism
The metabolism of Cefepime is minimal, as most of the drug is excreted unchanged. Only a small fraction is metabolized in the body to inactive compounds, with the majority eliminated via the kidneys.
Excretion
Cefepime is primarily excreted unchanged by the kidneys through glomerular filtration and tubular secretion. Its renal clearance is high, and dose adjustments are necessary in patients with impaired kidney function to prevent accumulation and toxicity.
PHARMACODYNAMICS
The pharmacodynamics of Cefepime are time-dependent, meaning its effectiveness relies on keeping drug levels above the minimum inhibitory concentration (MIC) of the bacteria. It kills bacteria by inhibiting cell wall synthesis and works against a broad range of Gram-positive and Gram-negative organisms, including many resistant strains.
DOSAGE AND ADMINISTRATION
The usual dosage of Cefepime for adults is 1–2 g every 8–12 hours intravenously, adjusted for infection severity and kidney function. It is typically administered as an IV infusion over 30 minutes, with dose reductions for patients with impaired renal function.
CONTRAINDICATIONS
Cefepime is contraindicated in patients with a known hypersensitivity to cefepime, other cephalosporins, or any component of the formulation.
DRUG INTERACTIONS
Aminoglycosides – co-administration can increase the risk of nephrotoxicity.
Loop diuretics – may enhance kidney-related side effects.
Probenecid – can decrease cefepime renal excretion, raising drug levels.
Other nephrotoxic drugs – concurrent use increases the risk of kidney damage.
FOOD INTERACTIONS
Cefepime has no significant food interactions. It can be administered with or without meals, as food does not affect its absorption, distribution, or overall effectiveness. This makes cefepime convenient for use in hospitalized patients and outpatient settings requiring intravenous or intramuscular administration.
SIDE EFFECTS
Gastrointestinal issues: nausea, vomiting, diarrhea
Rash or mild allergic reactions
Injection site reactions (pain or inflammation)
Serious (less common):
Neurotoxicity: seizures, confusion, encephalopathy, especially in patients with kidney impairment
Severe allergic reactions (anaphylaxis)
Clostridioides difficile–associated diarrhea
OVER DOSE
An overdose of Cefepime can lead to neurotoxicity, including seizures, encephalopathy, confusion, and myoclonus, especially in patients with impaired kidney function.
TOXICITY
Cefepime toxicity mainly affects the nervous system and kidneys. It can cause seizures, confusion, or encephalopathy, especially in patients with impaired renal function. Other toxic effects include gastrointestinal issues, blood disorders, and rare severe allergic reactions. Dose adjustments and monitoring kidney function help prevent toxicity.
